Azenta, Inc. · NASDAQ:AZTA
Azenta — UBS MedTech, Tools and Genomics Summit 2023
45 slides from Azenta's conference presentation, Aug 15, 2023
Slide 1: Azenta Life Sciences – UBS MedTech, Tools and Genomics Summit
Azenta Life Sciences UBS MedTech, Tools and Genomics Summit August 15, 2023
Slide 2: Safe Harbor Statement
Safe Harbor Statement “Safe Harbor” Statement under the U.S. Private Securities Litigation Reform Act of 1995; certain matters in this presentation, including forecasts of future demand and future Company performance, are forward-looking statements that are subject to risks and uncertainties that co
Slide 3: Agenda
AGENDA High Value Portfolio of Market Leading Offerings in Cold Chain of Custody and Sample Management Azenta – An Established Life Sciences Company with a Strong Track Record Unparalleled Multiomics Offerings 3 © 2023 Azenta, Inc. • Proprietary Information
Slide 4: Azenta – An Established Life Sciences Company with a Strong Track Record
Azenta – An Established Life Sciences Company with a Strong Track Record Market Leading Offerings: Growth Rate (YtY)1 Products Services Q3’23 YTD Q3’23 • Automated ultracold bio-sample 45% 55% storage • Biorepository services 25% 18% • Genomics services reported reported • Cold chain solutions for e
Slide 5: Azenta Portfolio – Diverse and Differentiated
Azenta Portfolio – Diverse and Differentiated Next Generation Sequencing B Medical 16% Sanger Systems Sequencing 17% 9% Gene Synthesis Products & Other Services 13% 45% Ultracold Systems 55% & Services 16% Sample Repository Consumables Solutions & Instruments 17% 12% Note: FY’23 Year-to-Date (9 mont
Slide 6: Strategically Positioned to Address Market Needs
Strategically Positioned to Address Market Needs 2X >30% >2,000 Growth in outsourced 2021 FDA drug approvals Cell & Gene Therapy active samples in 5 years require temperature control trials today1 • Increased requirements for • Regulations necessitate • CGT market poised for better sample management
Slide 7: Long Track Record of Growth Supported with Organic and M&A Investment
Long Track Record of Growth Supported with Organic and M&A Investment Revenue $700 Acquisitions COVID $600 Organic 33% CAGR $500 $ millions $400 $300 $200 $100 $- FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23E Note:FY23E based on the midpoint of FY’23 guidance as of August 8, 2023, and is being provi
Slide 8: Business Realignment Enhances Commercial Strategy and Supports Growth
Business Realignment Enhances Commercial Strategy and Supports Growth Sample 1 Management Solutions Operating 2 Multiomics Units 3 B Medical Three operational groups aligned with industry end-users and purchase decision-makers Note: Effective 10/1/23, at the start of FY24 8 © 2023 Azenta, Inc. • Pro
Slide 9: Continued Disciplined Approach to Capital Deployment
Continued Disciplined Approach to Capital Deployment Operational CapEx ~6-9% of Revenue Research & ~4-6% of Revenue Development Shareholder Returning Capital Through $1B Value Share Repurchases by CY23 End Strong Balance ~$1B Cash Available for Deployment* Sheet *Estimated based on $1.3B in cash as
Slide 10: Guidance As Provided August 8, 2023
Guidance As Provided August 8, 2023 Continuing Operations August Q3’22 Q4’22 Q1’23 Q2’23 Q3’23 Guidance Q4’23 * Total Revenue ($M) $133 $138 $178 $148 $166 $155 - $173 Organic Growth %* 6% 2% (1%) (8%) 2% ~(1)% Organic Growth ex-C&I %* 11% 9% 4% 1% 8% ~3% Adjusted EBITDA ($M)* $14 $9 $12 ($2) $13 $2
Slide 11: Differentiated End-to-End Sample Management Portfolio
Differentiated End-to-End Sample Management Portfolio ~$660M run-rate revenue, well-positioned for 1 growth and margin expansion in robust end markets Strong value proposition with Global platform that can support additional 2 capabilities and customers unique portfolio of sample-based solutions Hea
Slide 12: Agenda
AGENDA High Value Portfolio of Market Leading Offerings in Cold Chain of Custody and Sample Management Azenta – An Established Life Sciences Company with a Strong Track Record Unparalleled Multiomics Offerings 12 © 2023 Azenta, Inc. • Proprietary Information
Slide 13: What is Multiomics?
What is Multiomics? Geonomics Epigenomics Transcriptomics Proteomics Phenotype (DNA) (DNA Regulation) (RNA) (Protein) ~20,000 Coding Many Factors and >200,000 >1,000,000 Proteins Genes Modifications Impacting Transcripts >10,000,000 Modified Proteins Transcription Complexity 13 © 2023 Azenta, Inc. •
Slide 14: If It Can Be Sequenced, We Can Do It
Plasmid-EZ NEW • Whole Plasmid IF IT CAN BE SEQUENCED, Long-Read Sequencing WE CAN DO IT • One-stop shop with end-to-end support and integrated analysis • Specialization in clinical sample handling, transportation, storage and analysis • On-Site Regulatory laboratory offering a CAP/CLIA Environment
Slide 15: Why Azenta?
Why Azenta? ✓ Extraction through analysis ✓ Standard, custom, & exploratory workflows ✓ Experience with complex, difficult or potentially poor-quality samples Trusted 4,000+ 20/20 33 Top Pharmaceutical Nobel Laureate Partner for: Institutions Companies Labs 15 © 2023 Azenta, Inc. • Proprietary Infor
Slide 16: Azenta Offers Best-in-Class Multiomics Platforms
Azenta Offers Best-in-Class Multiomics Platforms Along with Experienced Provider Certifications CERTIFIED GLOBAL 10X CLINICAL RESEARCH ORGANIZATION 16 © 2023 Azenta, Inc. • Proprietary Information
Slide 17: Integrated Multiomics & Analytics to Unlock Sample Value
We Provide Integrated Multiomics & Analytics to Unlock Sample Value 1 2 3 4 5 6 7 Sample Sample Sample Sample Pre-analytical Sample Planning collection transportation annotation storage services Multiomics 17 © 2023 Azenta, Inc. • Proprietary Information
Slide 18: Study Design & Multiomics Processing Workflow
Study Design & Multiomics Processing Workflow Genomics Epigenomics Study Planning Sample Collection & & Sample Sourcing Isolation Transcriptomics & Immunoprofiling Proteomics Long Term Storage 18 © 2023 Azenta, Inc. • Proprietary Information
Slide 19: Multiomics Sample Processing Workflow
Multiomics Sample Processing Workflow What Can Happen? What Appears To Be Happening? What Makes It Happen? 19 © 2023 Azenta, Inc. • Proprietary Information
Slide 20: Multiomics Sample Processing Workflow - DNA
Multiomics Sample Processing Workflow - DNA What Can Happen? 20 © 2023 Azenta, Inc. • Proprietary Information
Slide 21: Genomics Solutions: Flexible & Overlapping Options
Genomics Solutions: Offering Flexible & Overlapping Options to Meet Needs Throughout Lifecycle of Study • Gold Standard • Most Common • Critical for Late Stage • Illumina and PacBio • Covers ~99% of gene coding • Customizable • Ideal for sequence variant and regions • Ideal for testing highly specif
Slide 22: Epigenomics Solutions: Cutting-Edge Methods
Epigenomics Solutions: Cutting-Edge Methods to Unlock Key Regulatory Elements in an Emerging Field Methyl-Seq (Illumina / PacBio) ✓ Comprehensive genome-wide analysis Methodology H3C selected depends ✓ Most traditional heavily on previous CH3 studies and background ATAC-Seq (Bulk/single-cell) knowle
Slide 23: Multiomics Sample Processing Workflow - RNA
Multiomics Sample Processing Workflow - RNA What Appears To Be Happening? 23 © 2023 Azenta, Inc. • Proprietary Information
Slide 24: RNA-Seq Assays - NGS Bestseller
RNA-Seq Assays - NGS Bestseller & Azenta’s Most Comprehensive Offering Bulk Single Cell Spatial Profiling • Extraction through analysis • Highly experienced industry experts • Critical for complex tissue samples • Illumina and PacBio in complex workflow • Characterize heterogeneity • Ultra-low input
Slide 25: Azenta-Optimized Protocols Enhance Quality of Final Results
Azenta-Optimized Protocols Enhance Quality of Final Results Making a Complex Workflow Manageable 25 © 2023 Azenta, Inc. • Proprietary Information
Slide 26: Interactive Analysis for Easy Publication-Ready Figures
Interactive Analysis for Easy Publication-Ready Figures • Deep data analysis – Enhance the way you explore your single-cell sequencing data through Azenta’s interactive data portal powered by Rosalind: • Ease of use with a clean and intuitive user interface • Rich data visualization to explore high-
Slide 27: Spatial Profiling for Limited Irreplaceable Archival Samples
Spatial Profiling is Ideal for Limited Irreplaceable Archival Samples With Interactive Consultation for Region Selection 27 © 2023 Azenta, Inc. • Proprietary Information
Slide 28: Multiomics Sample Processing Workflow - Protein
Multiomics Sample Processing Workflow - Protein What Makes It Happen? 28 © 2023 Azenta, Inc. • Proprietary Information
Slide 29: Proteomics – Early Adopter in Attractive Emerging Market
Proteomics – Early Adopter in Attractive Emerging Market with Expansive Growth Opportunities Sensitivity High Throughput Resolution Low abundance proteins in plasma can be detected without depletion Measuring 3000 proteins in only 6 ul of or fractionation plasma/serum Ease of Use Specificity One pla
Slide 30: NGS Critical for Confirmation & Validation of Biological Therapeutics
NGS is Also Critical for Confirmation & Validation of Biological Therapeutics DISCOVERY PRECLINICAL DEVELOPMENT CLINICAL DEVELOPMENT & USE Lead Model Process Therapeutic Target Discovery Clinical Trials Identification Development Optimization Delivery 30 © 2023 Azenta, Inc. • Proprietary Information
Slide 31: Synthesis and Sequencing Solutions for AAV Gene Therapies
Comprehensive Synthesis and Sequencing Solutions for Creating and Validating AAV Gene Therapies AAV TRANSGENE OR PLASMID SYNTHESIS Synthesize and clone transgene expression cassettes into custom AAV vectors PACKAGED AAV SEQUENCING AAV-ITR SEQUENCING Verify the integrity of packaged AAV vectors, meas
Slide 32: Synthesis and Sequencing for mRNA Therapeutics and Vaccines
Wave of the Future – Synthesis and Sequencing for Creating and Validating mRNA Therapeutics and Vaccines 32 © 2023 Azenta, Inc. • Proprietary Information
Slide 33: Azenta's Mission and Commitment
Azenta’s Mission and Commitment An end-to-end solution streamlined clinical testing and accelerated the timeline of the clinical study. DELIVER ANALYZE PROCESS Create report and Perform clinical deliver results Biological samples testing with custom accessioning and omics assay processing SOURCING C
Slide 34: Appendix
/ \ AZENTA LIFE SCIENCES Appendix
Slide 35: 10+ Years Building a Leading-Edge Life Sciences Company
10+ Years Building a Leading-Edge Life Sciences Company 2011-2012 2013-2014 2015-2016 2017-2018 2019-2020 2021 2022-2023 •BioCision 2 •GENEWIZ •Abeyance •Barkey •RTS •Matrical •FluidX •PBMMI •RURO •B Medical •Nexus •BioCision 1 •BioStorage •FreezerPro •Trans-Hit Azenta Life •Ziath Technologies •4tit
Slide 36: Portfolio Offering Examples
Portfolio Offering Examples Automated Stores Sample Repository Solutions B Medical Systems SampleStoreTM BioStoreTM BioStoreTM III Cryo Consumables & Instruments Genomic Services Sanger Gene Next Sequencing Synthesis Generation Sequencing 36 © 2023 Azenta, Inc. • Proprietary Information
Slide 37: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation Continuing Operations – Total Azenta $ millions, except EPS Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Revenue 139.7 145.5 132.7 137.6 178.4 148.4 165.9 GAAP gross profit 67.0 70.8 59.6 58.1 73.9 53.2 68.0 Gross profit margin 48.0% 48.7% 44.9% 42.3% 41.4%
Slide 38: GAAP to Non-GAAP Reconciliation – Segments
GAAP to Non-GAAP Reconciliation Continuing Operations – Segments $ millions, except EPS Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Life Sciences Products Revenue 49.9 53.6 47.4 48.4 89.7 58.9 74.6 GAAP gross profit 22.7 26.3 21.0 19.1 33.0 14.3 27.2 Gross profit margin 45.5% 49.0% 44.4%
Slide 39: Revenue and Gross Margin Quarterly Trend
Revenue and Gross Margin Quarterly Trend Continuing Operations Non GAAP Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Genomics Revenue 63.9 65.0 59.4 62.7 61.1 62.2 63.8 Genomics Gross Margin 32.6 32.1 27.3 28.2 28.9 28.2 29.5 Genomics Gross Margin % 51.0% 49.4% 46.0% 45.0% 47.4% 45.4% 46.
Slide 40: GAAP to Non-GAAP Reconciliation – Genomics and SRS
GAAP to Non-GAAP Reconciliation Continuing Operations – Genomics and SRS $ millions Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Life Sciences Services- Genomics Revenue 63.9 65.0 59.4 62.7 61.1 62.2 63.8 GAAP gross profit 31.1 31.1 25.9 26.5 27.7 27.0 28.3 Gross profit margin 48.7% 47.9%
Slide 41: GAAP to Non-GAAP Reconciliation – B Medical
GAAP to Non-GAAP Reconciliation Continuing Operations – B Medical and Products ex B Medical $ millions, except EPS Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 B Medical Revenue - - - - 41.8 15.1 26.8 GAAP gross profit - - - - 14.1 (1.3) 4.8 Gross profit margin - - - - 33.7% (8.7%) 17.9%
Slide 42: Net Income to Adjusted EBITDA Reconciliation
Net Income to Adjusted EBITDA Reconciliation Continuing Operations $ millions Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Net income 43.3 2,119.9 (9.6) (20.8) (11.2) (4.9) (1.5) (Income) Loss from discontinued operations, net of tax (40.5) (2,121.7) 2.6 15.5 - 2.9 (1.0) Net income (Loss)
Slide 43: Operating Profit to Adjusted EBITDA Reconciliation
Operating Profit to Adjusted EBITDA Reconciliation Continuing Operations – Segments Life Science Products Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Operating Profit (Loss) 4.2 5.0 2.0 (0.1) (3.8) (16.4) (4.9) Adjustments: Depreciation 0.7 0.9 0.9 1.2 3.1 3.3 2.9 Amortization of intangi
Slide 44: Operating Profit to Adjusted EBITDA Reconciliation – B Medical
Operating Profit to Adjusted EBITDA Reconciliation Continuing Operations – B Medical and Products ex B Medical B Medical Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Operating Profit (Loss) - - - - (0.5) (9.0) (4.1) Adjustments: Depreciation - - - - 2.1 2.0 1.9 Amortization of intangible
Slide 45: Calculation of Organic Revenue Excluding COVID
Calculation of Organic Revenue Excluding COVID Continuing Operations Growth Metrics $ millions Q1 FY22 Q2 FY22 Q3 FY22 Q4 FY22 Q1 FY23 Q2 FY23 Q3 FY23 Revenue 18% 12% 3% 0% 28% 2% 25% Acquisitions/divestitures (2%) (1%) 0% (3%) (33%) (13%) (24%) Currency exchange rates (0%) 1% 3% 4% 4% 3% 0% Organic